The importance of patient-centred drug development for amyotrophic lateral sclerosis.

Kiernan, Matthew C; Halliday, Glenda M; Rowe, Dominic B; Tan, Rachel H

Kiernan, Matthew C; Halliday, Glenda M; Rowe, Dominic B; Tan, Rachel H.

Afiliação

Kiernan MC; Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
Halliday GM; Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Rowe DB; Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
Tan RH; Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.

Neuropathol Appl Neurobiol ; 49(6): e12944, 2023 Dec.

Article em En | MEDLINE | ID: mdl-38148722

Assuntos

Esclerose Lateral Amiotrófica; Desenvolvimento de Medicamentos; Humanos; Esclerose Lateral Amiotrófica/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / Esclerose Lateral Amiotrófica Limite: Humans Idioma: En Revista: Neuropathol Appl Neurobiol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google